SCHEMBL5023294

SCHEMBL5023294

COc1ccc(Cn2c3ccc(Cl)cc3c3c(C(=O)Nc4c(Cl)cc(Cl)c[n+]4[O-])ccc(OC)c32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.41
FLT1 P17948 2/20 0.40
FLT4 P35916 2/20 0.40
KDR P35968 2/20 0.40
TP53 P04637 3/20 0.39
CCR2 P41597 1/20 0.39
ALDH1A1 P00352 2/20 0.37
LMNA P02545 2/20 0.37
POLB P06746 1/20 0.37
MEN1 O00255 1/20 0.37
RGS12 O14924 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
PKM P14618 1/20 0.37
TSHR P16473 1/20 0.37
NFKB1 P19838 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP2C19 P33261 1/20 0.37
GNAI1 P63096 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5025257 0.94 MAPT (0.42) MAPTFLT1FLT4KDRTP53
SCHEMBL5023319 0.88 CCR2 (0.41) MAPTFLT1FLT4KDRTP53
SCHEMBL5022809 0.82 PDE4D (0.49)
SCHEMBL5023302 0.81 MAPT (0.42) MAPTFLT1FLT4KDRTP53
SCHEMBL5546551 0.76 MAPT (0.48) MAPTTP53ALDH1A1LMNAPOLB
SCHEMBL5016454 0.76 PDE4D (0.49)
SCHEMBL5023496 0.74 KCNMA1 (0.54) MAPTTP53ALDH1A1LMNAMEN1
SCHEMBL5022391 0.74 PDE4D (0.50) MAPTTP53
SCHEMBL5017954 0.74 PIK3R1 (0.49) MAPTCCR2ALDH1A1LMNAMEN1
SCHEMBL5546407 0.74 LMNA (0.45) MAPTTP53ALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146810-A1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS S.A. (CH) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146810-A1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LTC4S, TSLP, GPR119 MAPT 783/4885FLT1 4142/4885FLT4 4084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.